MAZE NASDAQ
Maze Therapeutics, Inc.
1W: -2.6%
1M: -2.8%
3M: -41.8%
YTD: -35.2%
1Y: +154.7%
$25.78
+0.03 (+0.12%)
After Hours: $26.41 (+0.63, +2.44%)
Weekly Expected Move ±6.1%
$22
$24
$26
$27
$29
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.90
Bullish
1 bullish
0 neutral
0 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (47)
Maze Therapeutics Stock Still Up 180% After March Tumble. One Fund Just Disclosed Selling $3 Million in Shares
Maze Therapeutics, Inc. (MAZE) Reports Q1 Loss, Beats Revenue Estimates
Maze Therapeutics CSBO Sells 7,500 Shares for $190,000 After Strong Trial Results and Q4 Financials
Maze Therapeutics prices $150M equity offering
Maze Therapeutics Announces $150 Million Registered Offering
Equities Analysts Set Expectations for MAZE Q1 Earnings
Maze Therapeutics, Inc. (NASDAQ:MAZE) Receives Consensus Recommendation of “Buy” from Analysts
Maze Therapeutics' Chief Medical Officer Sold 100% of His Direct Holdings. Here's What This Means for Investors.
Harold Bernstein Sells 15,000 Shares of Maze Therapeutics (NASDAQ:MAZE) Stock
HC Wainwright Issues Optimistic Outlook for MAZE Earnings
After Plunging 30.8% in 4 Weeks, Here's Why the Trend Might Reverse for Maze Therapeutics, Inc. (MAZE)
Maze Therapeutics (NASDAQ:MAZE) Shares Up 5.5% After Better-Than-Expected Earnings
MAZE Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
Crude Oil Moves Lower; Cintas Raises FY2026 Forecast
Maze Insider Reports $736K Sale. Here's What Investors Should Know as Stock Plunges 33%
Dow Surges Over 300 Points; Chewy Shares Jump On Upbeat Earnings
Maze Therapeutics Stock Falls Despite Strong Phase 2 Kidney Drug Data For MZE829
12 Health Care Stocks Moving In Wednesday's Intraday Session
Indivior, Liquidia, Crinetics top Quant pharma list as Merck scoops up Terns for $6.7B
Maze Therapeutics falls despite positive mid-stage trial data for lead asset
Maze Therapeutics GAAP EPS of -$0.65 beats by $0.07
Earnings Scheduled For March 25, 2026
Maze Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights
Maze Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights
Harold Bernstein Sells 15,000 Shares of Maze Therapeutics (NASDAQ:MAZE) Stock
Maze Therapeutics President Sells All Insider Shares as Q4 Earning Report Nears
This Evommune Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Analysts Set Maze Therapeutics, Inc. (NASDAQ:MAZE) Price Target at $54.63
Maze Therapeutics (NASDAQ:MAZE) Sets New 1-Year High After Analyst Upgrade
545,132 Shares in Maze Therapeutics, Inc. $MAZE Acquired by ArrowMark Colorado Holdings LLC
This Strategy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Maze Therapeutics (NASDAQ:MAZE) Shares Gap Up on Analyst Upgrade
Maze Therapeutics Chief Medical Officer Sells 15K Shares As Company's Stock Continues to Surge
Maze Therapeutics Highlights Upcoming MZE829 Kidney Data, Maps Phase 2 Plans for MZE782 at Summit
Maze Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
Maze Therapeutics SVP Sells 5,000 Shares Amid Historic First Year for the Company's Stock
Maze Therapeutics: An Innovative, Nature-Driven Platform
Harold Bernstein Sells 25,156 Shares of Maze Therapeutics (NASDAQ:MAZE) Stock
What to Know About One Maze Insider's $3 Million Stock Sale as Shares Surge 150%
Maze Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Amy Bachrodt Sells 5,000 Shares of Maze Therapeutics (NASDAQ:MAZE) Stock
Amy Bachrodt Sells 10,000 Shares of Maze Therapeutics (NASDAQ:MAZE) Stock
Harold Bernstein Sells 45,000 Shares of Maze Therapeutics (NASDAQ:MAZE) Stock
Atul Dandekar Sells 72,400 Shares of Maze Therapeutics (NASDAQ:MAZE) Stock
Maze Therapeutics, Inc. (NASDAQ:MAZE) Given Consensus Recommendation of “Buy” by Analysts
Ensign Peak Advisors Inc Buys Shares of 18,539 Maze Therapeutics, Inc. $MAZE
Maze Therapeutics, Inc. (MAZE) Presents at Jefferies London Healthcare Conference 2025 Prepared Remarks Transcript